According to Kolbert, while there is a natural mechanism in place by which the cost of therapies will go down, there have been abuses of the system: &quot;we have noot seen a generic version of epipen,&amp;nbsp;even though there are companies like Adamis pharmaceuticals, which are waiting for Fda approval of their version of a generic epipen.&quot;